CD274 and small cell lung carcinoma: The immunotherapy revolution has reshaped ES-SCLC management, where the addition of PD-L1/PD-1 inhibitors (atezolizumab/durvalumab) to first-line chemotherapy demonstrated unprecedented survival benefits in pivotal phase III trials (5, 6).